Peptide Vaccine: A Literature Course on What the Studies Report

This course summarises the published peptide-vaccine literature in six modules. It describes what investigators built, which models they used, which endpoints they measured, and what they reported. It does not recommend anything. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health-related decision.

Module 1: What a peptide vaccine is and how it has been studied

Definition and class

A peptide vaccine is an immunisation approach in which short synthetic amino-acid sequences — fragments of a larger protein, usually chosen because they are presented to T cells or recognised by antibodies — are administered instead of a whole organism, a whole protein, or a nucleic acid encoding one. The class sits alongside live-attenuated, inactivated, subunit, viral-vector and mRNA platforms. A 2021 review in Molecular & Cellular Proteomics framed the platform's trajectory and the proteomic tools underpinning antigen selection in “The Peptide Vaccine of the Future”, which is the closest thing in this verified set to a general orientation piece.

Origins and forms in the literature

The published work is not one product but a family of constructs, and the forms differ substantially:

• Personalised tumour peptide vaccines — sequences selected per patient. A 2024 real-world observation in Nature Communications described patients with glioblastoma treated with a personalised peptide vaccine (PMID 39127809).
• Shared (off-the-shelf) tumour peptides — sequences common across patients. A 2025 npj Vaccines proteogenomic study applied immunopeptidomics to ovarian tumours and identified shared peptide vaccine candidates (PMID 40819132).
• Computationally designed multiepitope constructs — several epitopes strung together in silico, as in a melanoma design study (PMID 33226282) and a glioblastoma immunoinformatics design study (PMID 39340993).
• Anti-infective peptide vaccines — including a protocol chapter on a peptide vaccine against paracoccidioidomycosis (PMID 28584987), a SARS-CoV-2 peptide antigen discovery and adjuvant screening study (PMID 35456690), and a multivalent malaria vaccine targeting Plasmodium circumsporozoite protein and the mosquito protein AgTRIO (PMID 40804022).
• Self-antigen and non-infectious targets — a 2025 Aging Cell report described a CD38-targeting peptide vaccine in mice (PMID 40557469), and a 2018 study examined the peptide GV1001 in kanamycin/furosemide-treated mice (PMID 29403358).
• Formulation and delivery variants — peptide antigen paired with an immune-activating carrier, such as a STINGΔTM–cGAMP complex (PMID 35670244) or STING-agonist “drugamer” polymers (PMID 41183196).

Limits of the evidence (Module 1)

“Peptide vaccine” is a category label, not a single agent. Findings from a mouse ageing model do not transfer to a tumour vaccine, and a computationally designed construct is not the same evidentiary object as a construct given to patients. Any general statement about “peptide vaccines” therefore collapses studies that share a manufacturing logic and little else.

Module 2: Mechanism as described in the literature

The mechanistic chain described across these papers has three linked steps: antigen selection, presentation, and immune activation.

Step 1 — choosing the peptide

Antigen selection is where much of the published effort sits. The 2025 ovarian tumour study used a proteogenomic, immunopeptidomics-based approach — sequencing the peptides actually displayed by tumour HLA molecules — to nominate shared vaccine candidates (PMID 40819132). Where empirical immunopeptidomes were unavailable, researchers used prediction: the melanoma study applied an immunoinformatics workflow to design a novel multiepitope construct (PMID 33226282), and a 2024 study applied a comparable immunoinformatics approach to glioblastoma antigen design (PMID 39340993). For SARS-CoV-2, researchers combined peptide antigen discovery with screening of candidate adjuvant systems in the same programme (PMID 35456690).

Step 2 — presentation

Short peptides are described as acting at the level of MHC/HLA presentation: they are intended to occupy the groove of class I or class II molecules and be read by T-cell receptors. The 2021 review discussed this platform logic and the proteomic infrastructure supporting it (PMID 33583769). The personalised glioblastoma work is built on the same premise — peptides matched to a patient's own tumour and HLA type (PMID 39127809).

Step 3 — adjuvants and delivery

A recurring theme is that a bare peptide is weakly immunogenic, so the literature pairs it with an activating partner. A 2022 study delivered a peptide-based cancer vaccine via a STINGΔTM–cGAMP complex (PMID 35670244), and a 2025 PNAS study reported that peptide vaccine formulations built with structurally distinct STING-agonist drugamers induced discrete antitumor responses, indicating that the carrier chemistry itself shaped the response (PMID 41183196). The SARS-CoV-2 programme likewise treated adjuvant choice as an experimental variable rather than a fixed background (PMID 35456690).

Limits of the evidence (Module 2)

Mechanistic descriptions are largely inferred from design intent and immune readouts, not from direct in-human proof that a given epitope drove a given clinical outcome. Immunoinformatic designs demonstrate computational plausibility only. Because adjuvant and delivery choices measurably changed responses in at least one report (PMID 41183196), mechanism cannot be attributed to the peptide sequence in isolation.

Module 3: Reported outcomes, study by study

The table below organises the verified set by setting and by what each report stated. Effect wording is kept at the level the source itself used.

Oncology reports

The oncology strand is the largest. The glioblastoma observation is notable because it described real-world patients rather than a controlled trial cohort (PMID 39127809). The ovarian work stopped short of vaccination and delivered candidate antigens (PMID 40819132). The two STING-based reports addressed formulation efficacy in preclinical antitumor settings (PMID 35670244, PMID 41183196).

Non-oncology reports

Outside cancer, the reported endpoints were organ- or phenotype-specific: hearing function in an ototoxicity model with GV1001 (PMID 29403358), ageing-associated phenotypes in CD38-targeted mice (PMID 40557469), and pathogen-directed immunity against malaria, SARS-CoV-2 and Paracoccidioides (PMID 40804022, PMID 35456690, PMID 28584987).

Limits of the evidence (Module 3)

Most of these outcomes are preclinical or computational. Mouse phenotype rescue is not a human clinical endpoint. A real-world observational report is not randomised and cannot establish causal benefit (PMID 39127809). None of this constitutes evidence of benefit for any individual, and no benefit is being asserted here.

Module 4: Peptide Vaccine Side Effects: What Studies Report

Adverse-event reporting is where the verified set is thinnest, and it is important to say so plainly rather than to fill the gap.

Only one report in this set involved patients: the 2024 real-world observation of glioblastoma patients treated with a personalised peptide vaccine (PMID 39127809). Real-world observational designs of that type are the setting in which tolerability signals in humans would normally be captured, but no specific adverse-event rates, severities or discontinuation figures from that report are reproduced on this page, because the verified material available here does not supply them. Readers seeking those numbers should consult the primary publication directly.

The remaining reports were animal, in vitro, methodological or computational. The mouse studies — the CD38-targeting vaccine in ageing mice (PMID 40557469) and GV1001 in kanamycin/furosemide-treated mice (PMID 29403358) — reported efficacy-oriented phenotypic endpoints; animal tolerability data of that kind does not predict human safety. The paracoccidioidomycosis chapter is a protocol resource rather than a safety study (PMID 28584987), and the melanoma and glioblastoma immunoinformatics papers were design exercises in which allergenicity and toxicity were computational screening criteria, not observed clinical events (PMID 33226282, PMID 39340993).

One structural point about safety does emerge from the formulation literature: because responses differed by adjuvant chemistry in the STING drugamer work (PMID 41183196) and adjuvant systems were screened as a variable in the SARS-CoV-2 programme (PMID 35456690), the tolerability profile of a peptide vaccine is a property of the whole formulation, not of the peptide alone.

Limits of the evidence (Module 4)

There is no pooled safety database for “peptide vaccines” as a class in this set, no long-term follow-up, and no controlled comparison of adverse events against placebo. Absence of reported harm in a preclinical paper is not evidence of safety.

Module 5: Pharmacokinetics, where data exist

None of the verified papers in this course was a pharmacokinetic study, and no plasma concentrations, half-lives, clearance values or bioavailability figures are stated here, because the material available does not contain them. What the literature substitutes instead is formulation science aimed at the same underlying problem — short synthetic peptides are, as a class, rapidly handled by the body and poorly immunogenic on their own.

That problem is addressed indirectly in several reports. The 2022 delivery study coupled the peptide antigen to a STINGΔTM–cGAMP complex rather than administering free peptide (PMID 35670244). The 2025 PNAS work used polymeric drugamer carriers and reported that structurally distinct versions produced discrete antitumor responses (PMID 41183196). The SARS-CoV-2 study screened adjuvant systems alongside antigen discovery (PMID 35456690), and the 2021 review discussed platform-level development considerations (PMID 33583769). These are exposure-shaping strategies described qualitatively, not measured pharmacokinetics.

Limits of the evidence (Module 5)

Without measured exposure data, no statement can be made about dose proportionality, dosing intervals, accumulation or route comparisons. Formulation differences alone mean that PK, if it were measured, would not be transferable between the constructs described above.

Module 6: Regulatory status, stated factually

The constructs described in this course are investigational in the contexts their authors described. Immunoinformatic designs (PMID 33226282, PMID 39340993) exist only as computational candidates. Preclinical formulation and animal studies (PMID 35670244, PMID 40557469, PMID 29403358) sit upstream of human licensure. Antigen-discovery work identifies candidates rather than products (PMID 40819132).

Some general regulatory facts help frame that. In the United States, vaccines are licensed by the FDA under a Biologics License Application, a pathway distinct from small-molecule drug approval; an investigational vaccine is administered under an Investigational New Drug application in a trial or under specific expanded-access mechanisms. Separately, many synthetic peptides are distributed with “research use only” labelling, which signals that the material is not intended for human or veterinary administration and has not been reviewed for that purpose. Pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act applies to compounded drug preparations and is a separate legal framework again; it is not a substitute for vaccine licensure. Personalised, patient-specific products such as the one described in the real-world glioblastoma observation raise manufacturing and oversight questions that differ from those of off-the-shelf vaccines (PMID 39127809). Regulatory frameworks also vary by country.

These regulatory descriptions are factual summaries for education and are not legal advice.

Limits of the evidence (Module 6)

Approval status changes over time and by jurisdiction, and the verified papers here were not written as regulatory documents. Nothing in this module should be read as describing the current status of any specific named product.

What the studies did not test

Across the verified set, the following were not addressed:

1. Head-to-head comparison between peptide vaccines and mRNA, vector or whole-protein platforms for the same indication.
2. Long-term durability of any immune response, or long-term safety follow-up.
3. Use in healthy people — the ageing-phenotype work was conducted in mice, not humans (PMID 40557469).
4. Human translation of the animal findings, including the hearing endpoint reported in treated mice (PMID 29403358).
5. Randomised controlled comparison in the one real-world patient report (PMID 39127809).
6. Validation in vaccinated humans of the computationally designed constructs (PMID 33226282, PMID 39340993) or of the shared ovarian candidates (PMID 40819132).
7. Measured pharmacokinetics or defined dosing schedules in any of the papers summarised here.

The honest summary of this course is that peptide vaccines are an active, technically sophisticated research field with a wide range of targets and a narrow base of human outcome data. Researchers reported encouraging preclinical and design-stage findings; the study designs available here do not support claims about clinical benefit. This page is for educational purposes only and is not medical advice; consult a licensed physician regarding any medical question.

References

• A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine (Nature Communications, 2024)
• Peptide Vaccine Against Paracoccidioidomycosis (Methods in Molecular Biology, 2017)
• CD38-Targeting Peptide Vaccine Ameliorates Aging-Associated Phenotypes in Mice (Aging Cell, 2025)
• Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates (npj Vaccines, 2025)
• Peptide-Based Cancer Vaccine Delivery via the STINGΔTM-cGAMP Complex (Advanced Healthcare Materials, 2022)
• Peptide-Based Vaccine against SARS-CoV-2: Peptide Antigen Discovery and Screening of Adjuvant Systems (Pharmaceutics, 2022)
• Peptide vaccine formulations with structurally distinct STING agonist drugamers induce discrete, efficacious antitumor responses (PNAS, 2025)
• The Peptide Vaccine of the Future (Molecular & Cellular Proteomics, 2021)
• Designing a novel multiepitope peptide vaccine against melanoma using immunoinformatics approach (Journal of Biomolecular Structure & Dynamics, 2022)
• A Multivalent Peptide Vaccine Against Malaria, Targeting Plasmodium Circumsporozoite Protein and Mosquito AgTRIO (The Journal of Infectious Diseases, 2026)
• Peptide vaccine design against glioblastoma by applying immunoinformatics approach (International Immunopharmacology, 2024)
• Novel Peptide Vaccine GV1001 Rescues Hearing in Kanamycin/Furosemide-Treated Mice (Frontiers in Cellular Neuroscience, 2018)